The Oncology Institute Reports Third Quarter 2024 Financial Results ...

Predictive Oncology Reports Third Quarter 2024 Financial Results ...

Entered the $51.5 billion biomarker discovery market following compelling results from retrospective ovarian cancer study with UPMC Magee-Womens ...

Oncology Institute Inc Stock Price - TOI | ADVFN

The Oncology Institute Reports Third Quarter 2024 Financial Results. CERRITOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ ...

Q3 2024 Oncology Institute Inc Earnings Call Transcript - GuruFocus

Good afternoon and welcome to the Oncology Institute third quarter, 2024 earnings conference call. Today's call is being recorded and we have ...

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial ...

The decrease was primarily due to decreased spending in connection with our process development efforts related to our DNase platform. General ...

Oncology Institute Inc Stock Price Today | NASDAQ: TOI Live

Earnings call: The Oncology Institute reports strong growth in Q3 2024 · TOI stock touches 52-week low at $0.25 amid market challenges · The Oncology Institute ...

Gilead Sciences Announces Second Quarter 2024 Financial Results

Total second quarter 2024 revenue increased 5% to $7.0 billion, compared to the same period in 2023, primarily due to higher product sales in ...

Gritstone bio Reports First Quarter 2024 Financial Results and ...

General and administrative expenses were $8.5 million for the three months ended March 31, 2024 compared to $6.7 million for the three months ...

Nuvalent Highlights Corporate and Pipeline Achievements ...

... Reports Third Quarter 2024 Financial Results. Nuvalent, Inc ... Oncology (ESMO) Congress 2024. Data presented showed that treatment with ...

Checkpoint Therapeutics Reports Third Quarter 2024 Financial ...

Research and development expenses for the third quarter of 2024 included $0.5 million of non-cash stock expenses, compared to $0.3 million for ...

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial ...

Summary of Financial Results for Third Quarter 2024Net loss for the quarter ended September 30, 2024 was approximately $0.4 million. Research & ...

Predictive Oncology Reports Third Quarter 2024 Financial Results ...

Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update ; Revenue, $, 345,686 ; Cost of sales, 196,919 ...

Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)

As of November 6, 2024, the registrant had 75,559,075 shares of common stock outstanding. 2. THE ONCOLOGY INSTITUTE, INC. Form 10 ...

The Oncology Institute, Inc. (TOI) Stock Price, Quote & News

The Oncology Institute Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Guidance ... CERRITOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- ...

The Oncology Institute, Inc. (TOI) Stock Price, Quote, News & Analysis

Press Releases · The Oncology Institute Reports Third Quarter 2024 Financial Results · The Oncology Institute Announces Certification to Administer Pluvicto ...

The Oncology Institute Reports Third Quarter 2023 Financial Results ...

The Oncology Institute Reports Third Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance ; Patient services, $, 53,634 ...

AN2 Therapeutics Reports Third Quarter 2024 Financial Results ...

Net loss: Net loss for the third quarter of 2024 was $12.7 million, compared to $16.7 million for the same period during 2023. Cash Position: ...

Intensity Therapeutics Reports Third Quarter 2024 Financial Results ...

General and administrative expenses were $1.4 million for the three months ended September 30, 2024, compared to $1.1 million for the same ...

Lilly reports Q3 2024 financial results highlighted by strong volume ...

In Q3 2024, worldwide revenue was $11.44 billion, an increase of 20% compared with Q3 2023, driven by a 15% increase in volume and a 6% increase due to higher ...

Xenetic Biosciences Reports Third Quarter 2024 Financial Results

Net loss for the quarter ended September 30, 2024 was approximately $0.4 million. Research & development expenses for the three months ended ...

Incyte Reports 2024 Third Quarter Financial Results and Provides ...

Net product revenues of $20 million in the third quarter of 2024 ex- U.S. were primarily driven by sales in Germany and France . Additional ...